+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Votrient"

Kidney Cancer Drugs Global Market Report 2024 - Product Thumbnail Image

Kidney Cancer Drugs Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Renal Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Renal Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 180 Pages
  • Global
From
Votrient (pazopanib; Novartis) Drug Overview 2019 - Product Thumbnail Image

Votrient (pazopanib; Novartis) Drug Overview 2019

  • Report
  • March 2019
  • 21 Pages
  • Global
Votrient - API Insight, 2022 - Product Thumbnail Image

Votrient - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Votrient- Drug Insight, 2019 - Product Thumbnail Image

Votrient- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Votrient is a type of drug used to treat kidney cancer. It is a targeted therapy, meaning it works by targeting specific molecules involved in the growth and spread of cancer cells. Votrient works by blocking the action of certain proteins that help cancer cells grow and divide. It is used to treat advanced kidney cancer, and is often used in combination with other treatments such as chemotherapy and radiation therapy. Votrient is also used to treat other types of cancer, such as ovarian cancer and non-small cell lung cancer. Votrient is a relatively new drug, and is still in the early stages of development. It is not yet widely available, and is only approved for use in certain countries. However, it is gaining popularity as a treatment for kidney cancer, and is being studied for use in other types of cancer. Some companies in the Votrient market include Novartis, Pfizer, and AstraZeneca. These companies are researching and developing Votrient for use in treating kidney cancer and other types of cancer. Show Less Read more